Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

BeiGene, a global biotech firm that develops cancer medicines, has opened a 400,000-square-foot life sciences facility in ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s blockbuster Dupixent. Last year, BMS reported a phase 3 trial in eosinophilic ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...